AMS 800 Artificial Urinary Sphincter (AUS)
Boston Scientific Corp · Decision date Sep 14, 2026
What did the FDA decide?
This 30-day notice for supplement S142 to PMA P000053 describes a manufacturing process change for the AMS 800 Artificial Urinary Sphincter. The stated change is the use of new kink resistant endcaps and process changes to accommodate those endcaps.
The notice does not state what the new endcaps are made of, how the process changes were validated, or whether the change affects device performance. The supplement type is a 30-day notice, not a new approval of the whole system, and the stated purpose is not independent proof of safety or clinical effectiveness.
FDA approval order statement
use of new kink resistant endcaps and process changes to accommodate those endcaps
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Sep 14, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P000053/S142
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- EZY
- Decision code
- OK30
- Decision date
- Sep 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, incontinence, mechanical/hydraulic.
- Applicant
- Boston Scientific Corp
- Product code
- EZY
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000053. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000053 · Original PMA
AMS SPHINCTER 800 URINARY CONTROL SYSTEM
P000053/S142 received
Application receipt date recorded by FDA.
P000053/S142 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P000053. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000053
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Jun 14, 2001 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 100 Boston Scientific Way, Marlboro, MA, 01752
Sources and methodology
- Original FDA record: P000053/S142
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records